Advertisement

Radiation Therapy in Lymphoplasmacytic Lymphoma (Waldenström’s Macroglobulinemia)

  • Michael Oertel
  • Oliver Micke
  • Hans Theodor Eich
Living reference work entry

Abstract

Lymphoplasmacytic lymphoma is an exclusion diagnosis and is defined as a neoplasia occurring in older adults in which bone marrow (less frequently lymph nodes and spleen) is infiltrated by B lymphocytes, plasmacytoid lymphocytes, or plasma cells without the fulfillment of diagnostic criteria for any other small B-cell lymphoid neoplasm with putative plasmacytic differentiation (World Health Organization, WHO classification of tumours of haematopoietic and lymphoid tissues, revised 4th edition. International Agency for Research on Cancer, Lyon, 2017). With the presence of an additional monoclonal immunoglobulin M (IgM) gradient, the disease is called Waldenström’s macroglobulinemia (WM).

Since the first report by Jan Waldenström in 1944, after whom the disease was later named, symptomatic cytopenia, hyperviscosity, and globulin/serum protein excess have been described as disease characteristics (Waldenstrom J, Acta Med Scand 117:216–247, 1944).

Keywords

Lymphoma Indolent Lymphoplasmacytic Waldenström’s macroglobulinemia Stem cell transplantation 

References

  1. Anagnostopoulos A, Hari PN, Pérez WS, et al. Autologous or allogeneic stem cell transplantation in patients with Waldenstrom’s macroglobulinemia. Biol Blood Marrow Transplant. 2006;12:845–54.  https://doi.org/10.1016/j.bbmt.2006.04.010.CrossRefPubMedGoogle Scholar
  2. Anderson LD, Sandmaier BM, Maris MB, et al. Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT) for refractory Waldenstrom’s macroglobulinemia (WM): evidence for a Graft-Versus-WM effect. Blood. 2006;108:3034.CrossRefGoogle Scholar
  3. Buske C, Leblond V, Dimopoulos M, et al. Waldenstrom’s macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24:vi155–9.  https://doi.org/10.1093/annonc/mdt298.CrossRefPubMedGoogle Scholar
  4. Castillo JJ, Olszewski AJ, Kanan S, et al. Overall survival and competing risks of death in patients with Waldenström macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results database. Br J Haematol. 2015;169:81–9.  https://doi.org/10.1111/bjh.13264.CrossRefPubMedGoogle Scholar
  5. Castillo JJ, Garcia-Sanz R, Hatjiharissi E, et al. Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia. Br J Haematol. 2016;175:77–86.  https://doi.org/10.1111/bjh.14196.CrossRefPubMedPubMedCentralGoogle Scholar
  6. Davda R, Davies S, Kumaran T. Splenic irradiation in the management of Waldenstrom macroglobulinemia. Leuk Lymphoma. 2009;50:1047–9.  https://doi.org/10.1080/10428190902898263.CrossRefPubMedGoogle Scholar
  7. Dimopoulos MA, Anagnostopoulos A. Treatment of Waldenstrom’s macroglobulinemia. Curr Treat Options in Oncol. 2007;8:144–53.  https://doi.org/10.1007/s11864-007-0016-2.CrossRefGoogle Scholar
  8. Dimopoulos MA, Kyle RA, Anagnostopoulos A, Treon SP. Diagnosis and management of Waldenstrom’s macroglobulinemia. J Clin Oncol. 2005;23:1564–77.  https://doi.org/10.1200/JCO.2005.03.144.CrossRefPubMedGoogle Scholar
  9. Dreger P, Glass B, Kuse R, et al. Myeloablative radiochemotherapy followed by reinfusion of purged autologous stem cells for Waldenström’s macroglobulinaemia. Br J Haematol. 1999;106:115–8.CrossRefPubMedGoogle Scholar
  10. Duchesne GM, Harmer CL. Hemibody irradiation in lymphomas and related malignancies. Int J Radiat Oncol. 1985;11:2003–6.  https://doi.org/10.1016/0360-3016(85)90284-6.CrossRefGoogle Scholar
  11. Herrinton L, Weiss N. Incidence of Waldenstrom’s macroglobulinemia. Blood. 1993;82:3148.PubMedGoogle Scholar
  12. Jones RJ, Ambinder RF, Piantadosi S, Santos GW. Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood. 1991;77:649–53.PubMedGoogle Scholar
  13. Kastritis E, Kyrtsonis M-C, Hadjiharissi E, et al. Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom’s macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH). Leuk Res. 2010;34:1340–3.  https://doi.org/10.1016/j.leukres.2010.04.005.CrossRefPubMedGoogle Scholar
  14. Kastritis E, Kyrtsonis M-C, Hatjiharissi E, et al. No significant improvement in the outcome of patients with Waldenström’s macroglobulinemia treated over the last 25 years. Am J Hematol. 2011;86:479–83.  https://doi.org/10.1002/ajh.22027.CrossRefPubMedGoogle Scholar
  15. Kristinsson SY, Bjorkholm M, Goldin LR, et al. Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia patients: a population-based study in Sweden. Blood. 2008;112:3052–6.  https://doi.org/10.1182/blood-2008-06-162768.CrossRefPubMedPubMedCentralGoogle Scholar
  16. Kristinsson SY, Björkholm M, Landgren O. Survival in monoclonal gammopathy of undetermined significance and Waldenström macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2013a;13:187–90.  https://doi.org/10.1016/j.clml.2013.02.010.CrossRefPubMedGoogle Scholar
  17. Kristinsson SY, Eloranta S, Dickman PW, et al. Patterns of survival in lymphoplasmacytic lymphoma/waldenström macroglobulinemia: a population-based study of 1,555 patients diagnosed in Sweden from 1980 to 2005. Am J Hematol. 2013b;88:60–5.  https://doi.org/10.1002/ajh.23351.CrossRefPubMedGoogle Scholar
  18. Kyriakou C, Canals C, Cornelissen JJ, et al. Allogeneic stem-cell transplantation in patients with Waldenström macroglobulinemia: report from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2010;28:4926–34.  https://doi.org/10.1200/JCO.2009.27.3607.CrossRefPubMedGoogle Scholar
  19. Leblond V, Kastritis E, Advani R, et al. Treatment recommendations from the Eighth International Workshop on Waldenström’s Macroglobulinemia. Blood. 2016;128:1321–8.  https://doi.org/10.1182/blood-2016-04-711234.CrossRefPubMedGoogle Scholar
  20. Martino R, Shah A, Romero P, et al. Allogeneic bone marrow transplantation for advanced Waldenstrom’s macroglobulinemia. Bone Marrow Transplant. 1999;23:747–9.  https://doi.org/10.1038/sj.bmt.1701633.CrossRefPubMedGoogle Scholar
  21. Morel P, Duhamel A, Gobbi P, et al. International prognostic scoring system for Waldenstrom macroglobulinemia. Blood. 2009;113:4163–70.  https://doi.org/10.1182/blood-2008-08-174961.CrossRefPubMedGoogle Scholar
  22. Nakashima H, Saito B, Ariizumi H, et al. Splenic irradiation as a successful treatment for an elderly patient with B-cell prolymphocytic leukemia. Rinsho Ketsueki. 2008;49:1619–22.PubMedGoogle Scholar
  23. Sekhar J, Sanfilippo K, Zhang Q, et al. Waldenström macroglobulinemia: a surveillance, epidemiology, and end results database review from 1988 to 2005. Leuk Lymphoma. 2012;53:1625–6.  https://doi.org/10.3109/10428194.2012.656103.CrossRefPubMedGoogle Scholar
  24. Takemori N, Hirai K, Onodera R, et al. Durable remission after splenectomy for Waldenström’s macroglobulinemia with massive splenomegaly in leukemic phase. Leuk Lymphoma. 1997;26:387–93.  https://doi.org/10.3109/10428199709051789.CrossRefPubMedGoogle Scholar
  25. Tournilhac O, Leblond V, Tabrizi R, et al. Transplantation in Waldenstrom’s macroglobulinemia – the French experience. Semin Oncol. 2003;30:291–6.  https://doi.org/10.1053/sonc.2003.50048.CrossRefPubMedGoogle Scholar
  26. Waldenstrom J. Incipient myelomatosis or essential hyperglobulinemia with fibrinogenopenia – a new syndrome? Acta Med Scand. 1944;117:216–47.  https://doi.org/10.1111/j.0954-6820.1944.tb03955.x.CrossRefGoogle Scholar
  27. Wang H, Chen Y, Li F, et al. Temporal and geographic variations of Waldenstrom macroglobulinemia incidence: a large population-based study. Cancer. 2012;118:3793–800.  https://doi.org/10.1002/cncr.26627.CrossRefPubMedGoogle Scholar
  28. Wei Z, Yanxia Y, Ying X, et al. Splenic re-irradiation for waldenstrőm’s macroglobulinemia. Radiat Oncol Lond Engl. 2012;7:58.  https://doi.org/10.1186/1748-717X-7-58.CrossRefGoogle Scholar
  29. World Health Organization. WHO classification of tumours of haematopoietic and lymphoid tissues, revised 4th edition. Lyon: International Agency for Research on Cancer; 2017.Google Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Michael Oertel
    • 1
  • Oliver Micke
    • 2
  • Hans Theodor Eich
    • 1
  1. 1.Department of Radiation OncologyUniversity of MuensterMuensterGermany
  2. 2.Department of Radiotherapy and Radiation OncologyFranziskus HospitalBielefeldGermany

Personalised recommendations